what is known already: The PGD Consortium has collected, analysed and published 11 previous data sets since 1997. study design, size, duration: Data were collected from each participating centre using a pre-designed FileMaker Pro database (versions 5-10). Separate FileMaker Pro files were used for the cycles, pregnancies and baby records. The study documented cycles performed during the calendar year 2009 and follow-up of the pregnancies and babies born which resulted from these cycles (until October 2010).
Introduction
The European Society of Human Reproduction and Embryology (ESHRE) Preimplantation Genetic Diagnosis (PGD) Consortium, established in 1997, began collecting data on PGD cycles in 1999. To date, 11 data collections have been published, covering all applications of PGD, including autosomal and sex-linked monogenic diseases and chromosome abnormalities, preimplantation genetic screening (PGS) and social sex selection (ESHRE PGD Consortium Steering Committee, 1999 , 2000 Sermon et al., 2005 Sermon et al., , 2007 Harper et al., 2006 Harper et al., , 2008b Harper et al., , 2010b Goossens et al., , 2012 ). An overview was also published after 10 years of data collection (Harper et al., 2012) . This report summarizes data XII collected for the calendar year 2009 and the subsequent pregnancies. Data XII also includes the delivery rate for each indication.
Materials and Methods
Data were submitted by the centres using a FileMaker Pro database (versions 5 -10) . Separate files were used for the cycles, pregnancies and baby records, and for this data collection, the blank files were distributed to each PGD Consortium member centre at the end of 2008. The submitted data were thoroughly analysed to identify omissions and any ambivalent data entries. Corrections were requested from the participating centres. Records with incomplete data, for example with no cycle, no patient identification, no clear indication or from an incorrect time period, were excluded from the calculations. Detailed corrections and tables were made by expert co-authors. Clinical pregnancies were defined as the presence of one or more fetal hearts at 6 weeks of gestation. The implantation rate was defined as the number of fetal hearts per 100 embryos transferred. The delivery rate was defined as the percentage of pregnancies with delivery per oocyte retrieval (OR) and per embryo transfer procedure.
Results
The number of centres that join the PGD Consortium increases each year. This report includes data from 60 centres, who, as they submit full data on PGD cycles have the status of full PGD Consortium membership. The results are represented in tables according to an established layout. Accompanying text is deliberately concise and seven tables are available in an electronic version only: Supplementary data, Table SIIc lists the abnormal karyotypes carried by the patients undergoing PGD, Supplementary data, Table SIIIc lists the X-linked diseases for which sexing was carried out, Supplementary data, Table SIVc lists the monogenic diseases for which PGD was carried out, Supplementary data, Table SVIIIa (data I -XI) and Supplementary data, Table SVIIIb (data XII) list the complications of pregnancy and Supplementary data, Table SXIIa (data I -XI) and Supplementary data, Table SXIIb (data XII) list the congenital malformations and the neonatal complications. An overview of all cycles collected previously in data collections I -XI can be found in Table Ia , while an overview of the current data collection can be found in Table Ib . For all PGD/PGS cycles, ICSI was the method most often used for fertilization and cleavage-stage aspiration was the most commonly used method of biopsy. Overall, zona pellucida drilling was more commonly performed using a laser (Table Ib) . Tables IIa and IIb summarize the 870 cycles with OR collected for data collection XII, a total number that is still increasing and 12% higher than for data XI (774). In 84 cycles, PGD for a structural chromosome abnormality was simultaneously performed for aneuploidy screening, a 5-fold increase when compared with data XI. In 11 cycles, PGD was simultaneously performed for an additional fluorescence in situ hybridization (FISH) indication.
PGD cycles for structural chromosomal abnormalities
As for all years, data XII showed that PGD for reciprocal translocations was performed more often than for any other type of structural chromosome abnormality (60%). For reciprocal translocations, the number of cycles performed for female carriers more or less equals that for male carriers, whereas for Robertsonian translocations (29% of total cycles), the majority (63%) is performed for male carriers.
Overall, 42% of cycles were performed for infertile patients. The rate of infertility ranged from 33% in the group with female carriers of a reciprocal translocation up to 58% as observed in the group with Robertsonian translocations carried by the male partner.
The mean female age was 36 years, nearly 3 years more than the mean female age in the cumulative data I -XI. The increase is primarily caused by the women's age in the group of male reciprocal translocation carriers. In 84% of all cycles, ICSI was used for fertilization compared with 79% in data XI. Nearly all (98%) cycles to OR reached the biopsy stage. The use of laser drilling for zona breaching is still increasing and covers three-quarter of all cycles in data XII. Aspiration of blastomeres from cleavage stage embryos remains the preferred biopsy method (90%).
For data XII, 11 130 oocytes were collected, a mean of 12.8 per cycle. Of these, 62% (6845/11 130) were fertilized (2 pronuclei) and 76% (5176/6 845) of the resulting embryos were biopsied. Of the embryos successfully biopsied, 94% (4798/5122) gave a diagnostic result, of which only 27% (1275/4798) were transferable. As expected, the lowest percentage of transferable embryos was found in the reciprocal translocation group (22% for male carriers and 20% for female carriers), whereas generally 40% of embryos were transferable in the male carrier of a Robertsonian translocation group, the deletion group and the inversion group. Of all transferable embryos, 70% were actually transferred and 14% were frozen.
From 870 cycles to OR, only 66% resulted in an embryo transfer procedure (ranging from 80% for male Robertsonian translocation carriers and carriers of an inversion to 54% for carriers of a deletion). This is in agreement with previous data showing that a high level of chromosomally abnormal embryos is found in patients carrying chromosomal abnormalities.
A positive hCG was obtained in 239 cycles, with a positive heart beat in 187 cycles (21% per OR and 33% per embryo transfer). The clinical pregnancy rates per OR were higher for Robertsonian translocation carriers when compared with reciprocal translocation carriers, but this difference almost disappeared when comparing clinical pregnancy rate per embryo transfer. Overall, the implantation rate was 25% (218/891 (10% per clinical pregnancy), half of them occurring in the female reciprocal translocation group. Eighteen clinical pregnancies were lost to follow-up. Tables IIIa and IIIb summarize the 1263 and 113 Tables IVa and IVb summarize the 6096 and 1597 Two cycles were on frozen-thawed embryos only so they were not counted as cycles with an OR, but were counted as cycles going to PGD. Continued cycles in combination with HLA compatibility, see below), cystic fibrosis (CF) (140 cycles and 9 cycles for CF and a second indication) and spinal muscular atrophy (SMA) (52 cycles and another 6 for SMA and a second indication). Amongst the autosomal dominant diseases, most PGD cycles were performed for Huntington disease (136 cycles) and myotonic dystrophy type I (DM1) (119 cycles, plus 5 cycles for DM1 and a second indication), neurofibromatosis type 1 (43 cycles, plus 2 cycles for neurofibromatosis type 1 and a second indication) and familial adenomateous polyposis coli (30 cycles of which 3 cycles were combined with a second indication). For a specific diagnosis of X-linked diseases the most common indications were for fragile X syndrome (121 cycles and another 4 cycles combined with PGS), Duchenne and Becker muscular dystrophy (DMD/BMD) (51 cycles and 2 cycles for DMD and a second indication) and haemophilia A and B (17 cycles and 3 cycles, respectively). There were 40 cycles for HLA compatibility typing only (of which 5 were in combination with PGS) and 78 cycles for HLA typing along with a specific disorder. The most common indication here was beta-thalassemia/sickle cell anaemia (52 cycles). The total number of cycles with HLA typing which had decreased from 151 cycles in data X to 138 cycles in data XI has further decreased to 118 cycles in the current data collection. For data XII, ICSI was used in the majority of cycles (98.4% of cycles to OR) and PCR was still the most widely used first-line method of DNA amplification (91.2% of cycles to OR). The percentage of cycles relying on whole genome amplification as method of DNA amplification (6.1% of cycles to OR) was not different from previous data collection (5.1%). In a small number of cycles (2.6%) both PCR and FISH methods were carried out.
PGD cycles for sexing for X-linked diseases

PGD cycles for monogenic diseases
The use of laser was the preferred method for biopsy (75.7% of cycles to PGD); acidic tyrode or mechanical action was applied in 17.1 and 7.2% of cycles to PGD, respectively. Day 3 cleavage-stage embryo biopsy was most frequently used (97.2% of cycles to PGD). Genetic testing was carried out on either 1 cell (47.3% of cycles to PGD) or 2 cells per embryo (38.6% of cycles to PGD). In 13.2% of cycles a mixture of 1 and 2 cells, 3 cells or trophectoderm biopsy was applied. A total number of 21 330 cumulus -oocyte complexes (COCs) were collected and 80.4% of the mature oocytes which were inseminated 
Preimplantation genetic screening
The application of PGD to identify numerical chromosome errors (aneuploidies) in embryos, so-called PGS, was first reported by the PGD Consortium in data collections I-III for 787 cycles when it constituted 36% of all reported PGD (Harper et al., 2012) . Overall, 3551 cycles of PGS are reported in data collection XII (Table  Vb) . The mean age of women undergoing PGS was 38.9 years. PGS was applied to cycles in women of advanced maternal age, those who had suffered from repeated implantation failure, repeated miscarriage, experience of a previous abnormal pregnancy, severe male factor and in some cases for more than one indication.
In the PGS group, a total number of 32 088 oocytes were inseminated, 23 337 (72.7%) were fertilized, 18 991 embryos were biopsied and 17 905 (94.6% of successfully biopsied) were diagnosed. Of these 6092 were transferrable, 4527 were transferred and 930 were frozen.
A total number of 2623 cycles with embryo transfer were performed with 1031 hCG-positive result. PGS represents 58% of all the PGD cycles to embryo transfer in the data collection XII. Positive heart beat was reported for 831 cycles, with a clinical pregnancy rate per embryo transfer of 31.7% (23.4% per OR) and an implantation rate (fetal hearts/100 embryos transferred) of 22.6%. The delivery rate per embryo transfer was 22.8% and the miscarriage rate per clinical pregnancy was 16.8%. A total number of 109 clinical pregnancies were lost to follow-up. (71/201) were transferable (of the desired sex). In total, 37 embryos were transferred in 24/29 cycles initiated, with 6 cycles resulting in a hCG-positive test, and a fetal heartbeat was subsequently detected in 5 of these pregnancies, 1 of which was a twin pregnancy and the remaining 4 were singletons. Four pregnancies went to term and delivered four babies. The method of genetic analysis was FISH for all 29 cycles, of which 2 cycles were analysed also by PCR. The number of cycles for social sexing in data XII represents a relative increase from those reported in data XI (just 5 cycles) but it is lower than the number reported in data X (92 cycles). Overall, the number of cycles reported for social sexing may be biased according to the number of centres offering this service, which are relatively few anyway (only six full Consortium membercentres Continued ESHRE PGD consortium data collection XII pregnancy reported. This reduction compared with previous data collections was partly due to premature birth no longer being included as a complication of pregnancy. The delivery rates per indication are reported in Tables IIb, IIIb , IVb, Vb and VIb. Caesarean section was performed for 52% of the deliveries (557/1062) ( Table IXb) . In 83 cases, the method of delivery was not known. Confirmation of the diagnosis was performed prenatally (197/548) and/or post-natally (351/548) ( Table Xb) . Table Xb and Supplementary data, Table SXIIb show the abnormalities found during pregnancy or post-natally. A malformation was described in 20 singletons and 2 twins out of 863 babies documented. Several abnormalities were found that were not related to PGD indication. This report again confirms that pregnancies and babies born after PGD are very similar to the pregnancies obtained and babies born after ICSI treatment (Bonduelle et al., 2002) . In our series, the number of multiple pregnancies remains high (275/1296, 22%) , which indicates that 34% (432/1169) of all babies born are part of a multiplet at birth ( One triplet resulted in a singleton due to reduction of one fetus and vanishing of another fetus. h One triplet: fetal reduction, followed by amniocentesis and loss of remaining twin at 16 weeks (1 fetal sac counted in reduction, 2 in miscarriage, 1 s trimester pregnancy loss after miscarriage counted). i TOP after misdiagnosis: one misdiagnosis for sexing, FISH, female fetus, indication SS; one misdiagnosis for b-thalassemia, PCR; one misdiagnosis for DM1, PCR, one misdiagnosis after PGS, karyotype 45,X; one misdiagnosis for a reciprocal translocation 46,XY,der(15)t(13;15)(q25.1;q26.3). TOP after ultrasound (four): enlarged lateral ventricle, two singletons with cardiopathy, one singleton with tetralogy of Fallot. TOP after amniocentesis, not related to the PGD: trisomy 18, indication for PGD parent carrier of reciprocal translocation not involving chromosome 18; one polymalformation; one cystic hygroma, failed karyotype; one Turner mosaic, one spina bifida, 5 trisomy 21 pregnancies, one mosaic 46,XY/47,XY+18 (misdiagnosis), one hemivertebrae, hypoplastic cerebellum, hydrocephaly (46,XX), one abnormal chromosome 15, one polycystic kidney, one Finnish nefrosis twin (both affected), one confirmed cytomegalovirus infection, one elective termination (unknown cause) and one hydrocephaly termination of a 8-month pregnancy [started as quadruplet: two selective reductions, one miscarriage after chorionic villus sampling (CVS) and the last fetus TOP]. One TOP for misdiagnosis of reciprocal translocation, one TOP for Down's syndrome following PGD for HLA compatibility, one TOP for complication in pregnancy following PGD for neurofibromatosis Type 1. One TOP for acrania following PGD for CF, one TOP for severe growth retardation following PGD for Fragile X, one TOP for agensis corpus callosum following PGS for maternal age, one TOP for limb body wall defect following PGS for AS male factor, one TOP for neural tube defect following PGS for male factor, twin TOP for Down's syndrome risk following PGS for male factor, one TOP due to malformation at 16 weeks in remaining twins where first twin miscarried at 8 weeks.
PGD cycles for social sexing
Misdiagnoses
Table XIIIa summarizes the misdiagnoses reported for data I -XI, with no misdiagnoses reported in data X and data XI. In data XII (Table XIIIb) , three adverse misdiagnoses from FISH are reported which were identified by prenatal diagnosis. Two were following PGS for maternal age and recurrent miscarriages; of which one was a misdiagnosed sex of which the pregnancy was continued to delivery and one was a trisomy 21 which miscarried. The third case was after PGD for a reciprocal translocation where the fetus was found to have the karyotype 46,XY,der(17)t(5;17)(p13;p13)mat and termination of pregnancy (TOP) was performed. No misdiagnosis was reported for monogenic PGD cycles. Figure 1 shows the pregnancy rate per centre for data XII. The pregnancy rate ranges from 0 to 100% with an average of 23.04%, compared with 21.27% for data XI and 21% for data X. As previously observed, pregnancy rates are not correlated with the number of cycles that each centre performs, and the findings indicate that some of the most active centres fall below the average 23.04% pregnancy rate and even have pregnancy rates lower than some of the centres performing only a few cycles.
Success of individual centres
Discussion
This 12th data report of the ESHRE PGD Consortium demonstrates an increase (9.2%) in the number of PGD cycles, and related pregnancies and babies. There were a couple of notable trends in data XII compared with previous years. The first was that the global pregnancy rate per OR improved compared with previous years (23 versus 21.7 and 21.0% for data XI and X, respectively), even though there was no change in the mean ages of the women undergoing PGD, the indications for PGD cycles, the number of oocytes retrieved and the number of biopsied embryos. The other trend was that for monogenic PGD cycles, 1-cell biopsy was more frequently applied than 2-cell biopsy in data XII cycles, in contrast to previous data collections. This could reflect the development of more robust multiplex PCR assays which support improved diagnostic accuracy. The three cases with a misdiagnosis result reported in data XII were all for cases analysed with FISH; no cases were reported for PCR-based monogenic PCR. This is in contrast to data reported so far on misdiagnosis in PGD (Wilton et al., 2009) , whereby misdiagnosis for FISH-based PGD is reported to be much less common than that for PCR-based PGD (0.1 compared with 0.5%, respectively). This recent change may be explained by the general improvement of PCR-based tests in recent years, although it could also be a coincidental finding within data XII.
Of the misdiagnosis reported in data XII, two were from the same centre following PGS for maternal age and recurrent miscarriages. One was a misdiagnosed sex, constituting a benign misdiagnosis, and the pregnancy was continued to delivery. The other one was a trisomy 21 which miscarried. The third case, from another centre, was after PGD for a reciprocal translocation where the fetus was found to have the karyotype 46,XY,der(17)t(5;17)(p13;p13)mat during prenatal diagnosis, and TOP was performed.
To date, including all cycles up to data XII, misdiagnosis has been reported for only 12/7759 PCR-based cycles and 19/30 965 FISHbased PGD cycles. However, these numbers may not reflect the true misdiagnosis in PGD, as many embryo transfers have no follow-up (no pregnancy or birth), and only a minority of centres perform audit through re-analysis of untransferred supernumerary embryos. Due the importance of evaluating the diagnostic accuracy in PGD and PGS, and additionally identifying potential pitfalls in methods or the biological limits posed by the samples, the PGD Consortium set-up two multicentre studies to re-analyse embryos following either PCR-based PGD or FISH-based PGD. Both studies compared results at the time of PGD with the results of the embryo follow-up analysis in a large cohort of samples. The evaluation of the concordance of FISH-based analysis at PGD and follow-up was difficult and the results have not been finalized. However, the PCR-based PGD study in fact demonstrated the validity, robustness and high diagnostic value of PCR-based PGD protocols in current use by the PGD community (Dreesen et al., 2013, accepted) . Thus, it is likely that misdiagnosis is in fact minimal in PGD, indicating that overall PGD centres apply high standards in PGD practice, as outlined in the Best Practice Guidelines (Harton et al, 2011ab,c,d complete data on the PGD cycles and associate membership for centres who send in summary data. The latter are usually satellite PGD centres that collaborate with more than one IVF centre and often do not have access to information about the IVF cycles (associate members also included IVF laboratories performing transport PGD with a centre that is a full member, as well as new member centres). However, for data XII, very few associate centres (only four) sent in summary data and so these data were not included in this report. Due to the low response rate, the information requested for associated centres in the summary data they submit will be amended to include even fewer details. The Steering Committee (SC) considers that even only basic data such as the numbers and on minimal details on the genetic diagnosis in PGD cycles are important for the data collections. Data collection is a very time consuming activity for all involved, including the centres that make the effort to submit data as well as the curators of the data. For this reason, the evaluation and publication of data collections is lagging. The SC acknowledges the effort of all contributing centres and aims to address the lag as soon as possible, although it is planned that by the end of 2014 there will be an on-line data submission platform ready for all consortium members to use. However, since the data collections do not represent real-time trends in PGD, the PGD Consortium SC has initiated a working group to monitor the introduction and application of new technologies in PGD. All PGD centres have been sent a questionnaire that they are invited to complete, which aims to evaluate the introduction of new technologies at all stages in PGD, including gamete fertilization, embryo biopsy practice and genetic testing strategies and technologies.
Overall, the data collection provides an extremely valuable resource for data mining and for following trends in PGD practice. Including all the cycles submitted from data I until data collections XIII and XIV (the latter including PGD cycles carried out between January and December 2010 or 2011 with babies delivered up to 2011 or 2012, respectively), the Consortium will have information on almost 52 000 cycles. So far a preliminary data mining effort has been initiated, including data collection IV through to XI (.29 000 cycles). This data set should highlight the trends in PGD practice over the earlier years. The aim is to be able to follow all trends in PGD practice more closely in order to facilitate selecting the most appropriate and optimized approach for each patient undergoing a clinical PGD cycle.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/.
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